Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Caffeine and sodium benzoate injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Accidental caffeine poisoning |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
|
Intentional caffeine poisoning |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
|
intoxication par la caféine d'intention indéterminée |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
1 |
Caffeine overdose |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Accidental caffeine overdose (disorder) |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Intentional caffeine overdose |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
surdose de caféine d'intention indéterminée |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
1 |
Caffeine-related disorder |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Organic mental disorder caused by caffeine (disorder) |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Plasma caffeine measurement |
Component |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Serum caffeine measurement |
Component |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Caffeine solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine 5mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine citrate 20mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine citrate 20mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine + ergotamine tartrate 100mg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine + ergotamine tartrate 100mg/2mg suppository (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine measurement |
Component |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Aspirin + caffeine + orphenadrine citrate tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Caffeine-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing caffeine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Caffeine-induced sleep disorder |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Poisoning by caffeine |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Caffeine-induced anxiety disorder |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Caffeine intoxication |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Caffeine withdrawal |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
1 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing aspirin and butalbital and caffeine and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine and isometheptene mucate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing aspirin and caffeine and propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing aspirin and caffeine and dihydrocodeine tartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine + ergotamine tartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine and sodium benzoate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
2 |
Product containing butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Aspirin + caffeine + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing butalbital and caffeine and codeine phosphate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing aspirin and butalbital and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine 100 mg and ergotamine tartrate 2 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine and dihydrocodeine tartrate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing aspirin and caffeine and cinnamedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing aspirin and caffeine and orphenadrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing caffeine and paracetamol and salicylamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
2 |
Product containing buffered aspirin and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing aspirin and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing aspirin and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Ergotamine + caffeine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine citrate |
Is a |
False |
Caffeine |
Inferred relationship |
Some |
|
Intentional caffeine poisoning |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
[X]Adverse reaction to caffeine |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely caffeine 65 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine 25 mg and paracetamol 450 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Accidental poisoning by caffeine |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Adverse reaction to caffeine |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Allergy to caffeine |
Causative agent (attribute) |
False |
Caffeine |
Inferred relationship |
Some |
|
Product containing caffeine and ergotamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing ammonium chloride and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Product containing caffeine and glucose (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Fioricet with codeine 325mg/50mg/40mg/30mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
|
Caffeine dependence (disorder) |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Allergy to caffeine |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
A pattern of caffeine use that has caused clinically significant harm to a person's physical or mental health or in which caffeine-induced behaviour has caused clinically significant harm to the health of other people. The pattern of caffeine use is evident over a period of at least 12 months if use is episodic and at least one month if use is continuous (daily or almost daily). Harm may be caused by the intoxicating effects of caffeine, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration. |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
4 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
4 |
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
3 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Caffeine 25 mg and paracetamol 450 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
3 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
3 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Caffeine |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |